COMMUNIQUÉS West-GlobeNewswire

Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
08/06/2026
Results from Rhapsido (remibrutinib) pivotal Phase III RemIND trial, the largest study in chronic inducible urticaria, to be highlighted in late-breaker oral presentation New Phase IIIb REMIXED extension data in chronic [...]
Intravacc met en avant ses capacités analytiques intégrées destinées à accélérer le développement de vaccins et de produits biologiques
08/06/2026
Ses services analytiques de pointe accompagnent les partenaires à chaque étape, de la caractérisation des produits et du développement des tests à la mise en conformité aux BPF et à la fabrication clinique Intravacc [...]
Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®
08/06/2026
REYKJAVIK, Iceland, June 08, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, [...]
Amphista Therapeutics announces FDA clearance of IND application for AMX-883, its lead Targeted Glue™ degrader for acute myeloid leukaemia
08/06/2026
Amphista to initiate its first clinical trial for AMX-883, a potent, orally bioavailable DCAF16-dependent degrader of BRD9, for acute myeloid leukaemia (AML) in H2 2026 The Phase 1 monotherapy dose-escalation and [...]
Intravacc Highlights Integrated Analytical Capabilities to Accelerate Vaccine and Biologics Development
08/06/2026
Advanced analytical services support partners from product characterization and assay development to GMP readiness and clinical manufacturing Intravacc offers state-of-the-art analytical methods for identity, content, [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
08/06/2026
COPENHAGEN, Denmark, June 8, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on June 2, 2026, under which the Company will repurchase shares for an amount up to [...]
Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®
08/06/2026
REYKJAVIK, Iceland, June 8, 2026 - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that [...]
Virbac: modalités de mise à disposition ou de consultation des documents préparatoires à l'assemblée générale mixte du 29 juin 2026
08/06/2026
Les actionnaires de la société VIRBAC sont invités à participer à l’assemblée générale mixte qui se tiendra le lundi 29 juin 2026 à 14 heures , dans les bâtiments de VIRBAC direction, 13 ème rue LID 06517 Carros. L’avis [...]
Vivoryon Therapeutics N.V. to Report Q1 2026 Financial Results on June 11, 2026
08/06/2026
Vivoryon Therapeutics N.V. to Report Q1 2026 Financial Results on June 11, 2026 Halle (Saale) / Munich, Germany, June 8, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical [...]
Communiqué de presse : Sarclisa en formulation sous-cutanée de Sanofi approuvé dans l’UE comme premier traitement anticancéreux administré via un injecteur portable
08/06/2026
Sarclisa en formulation sous-cutanée de Sanofi approuvé dans l’UE comme premier traitement anticancéreux administré via un injecteur portable Sarclisa administré via l’injecteur portable CirCLIQ ® offre une expérience [...]
IBA signe un contrat pour installer deux solutions de protonthérapie Proteus®ONE avec un grand centre médical universitaire aux États-Unis
08/06/2026
Louvain-la-Neuve, Belgique, le 8 juin 2026 - IBA (Ion Beam Applications S.A., EURONEXT), leader mondial des technologies d’accélération de particules et principal fournisseur de solutions de protonthérapie pour le [...]
Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology
08/06/2026
Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell malignancies Collaboration adds to Roche’s oncology pipeline and offers potential indications in immunology [...]
Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
08/06/2026
Strategic collaboration combines Nurix’s leadership in targeted protein degradation with Roche’s portfolio of B-cell targeted therapies and global clinical and commercialization footprint Robust clinical development [...]
Rappel : les BSA Nicox de juin 2024 expireront le 19 juin 2026
08/06/2026
Communiqué de presse Rappel : les BSA Nicox de juin 2024 expireront le 19 juin 2026 8 juin 2026 – publication à 7H30 Sophia Antipolis, France Nicox SA (Euronext Growth Paris : FR0013018124, ALCOX, éligible PEA-PME), une [...]
Press Release: Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector
08/06/2026
Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector Sarclisa administered via the CirCLIQ ® OBI offers a treatment experience designed around the [...]
IBA signs contract with a major U.S. academic medical center to install two Proteus®ONE proton therapy solutions
08/06/2026
Louvain-La-Neuve, Belgium, June 08, 2026 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment [...]
Reminder: Nicox June 2024 Warrants will expire June 19, 2026
08/06/2026
Press Release Reminder: Nicox June 2024 Warrants will expire June 19, 2026 June 8, 2026 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international [...]
GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Position as a Global Biopharmaceutical Company
08/06/2026
Transaction Establishes a Large-Scale Pharmaceutical Platform in Japan and Strengthens Commercial Capabilities Across Key Therapeutic Areas TOKYO, June 07, 2026 (GLOBE NEWSWIRE) -- GNI Group Co., Ltd. (TSE: 2160) today [...]
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
08/06/2026
The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027 SAN DIEGO, June 07, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ, “LENZ” or the “Company [...]

Pages